[go: up one dir, main page]

DK4244252T3 - Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof - Google Patents

Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof Download PDF

Info

Publication number
DK4244252T3
DK4244252T3 DK22769624.2T DK22769624T DK4244252T3 DK 4244252 T3 DK4244252 T3 DK 4244252T3 DK 22769624 T DK22769624 T DK 22769624T DK 4244252 T3 DK4244252 T3 DK 4244252T3
Authority
DK
Denmark
Prior art keywords
interleukin
antibody
treatment
pulmonary disease
chronic obstructive
Prior art date
Application number
DK22769624.2T
Other languages
English (en)
Inventor
Muhammad Waqas Sadiq
Eulalia Jimenez Lozano
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of DK4244252T3 publication Critical patent/DK4244252T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK22769624.2T 2021-08-27 2022-08-26 Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof DK4244252T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163237630P 2021-08-27 2021-08-27
US202263364734P 2022-05-16 2022-05-16
PCT/EP2022/073766 WO2023025932A1 (en) 2021-08-27 2022-08-26 Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody

Publications (1)

Publication Number Publication Date
DK4244252T3 true DK4244252T3 (da) 2024-09-02

Family

ID=83319064

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22769624.2T DK4244252T3 (da) 2021-08-27 2022-08-26 Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof

Country Status (16)

Country Link
US (1) US20250136676A1 (da)
EP (1) EP4244252B1 (da)
JP (1) JP7591691B2 (da)
KR (2) KR20240049348A (da)
CN (2) CN120392998A (da)
AU (1) AU2022335719B2 (da)
CA (1) CA3229249A1 (da)
DK (1) DK4244252T3 (da)
ES (1) ES2991847T3 (da)
FI (1) FI4244252T3 (da)
HU (1) HUE068111T2 (da)
IL (1) IL310926B2 (da)
PL (1) PL4244252T3 (da)
PT (1) PT4244252T (da)
TW (1) TW202327648A (da)
WO (1) WO2023025932A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210099A1 (en) * 2024-04-04 2025-10-09 Medimmune Limited Method of treatment and selecting a subject
WO2025242619A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Treatment for mucus plugging
WO2025242618A1 (en) * 2024-05-20 2025-11-27 Medimmune Limited Bronchiectasis treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
HUE053097T2 (hu) 2015-03-31 2021-06-28 Medimmune Ltd Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
EP3962515A1 (en) 2019-05-01 2022-03-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
EP4054711A1 (en) 2019-11-04 2022-09-14 MedImmune Limited Methods of using il-33 antagonists
PH12022552371A1 (en) * 2020-03-13 2023-12-18 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
CN115551542A (zh) * 2020-05-11 2022-12-30 免疫医疗有限公司 抗il-33抗体的配制品

Also Published As

Publication number Publication date
EP4244252B1 (en) 2024-05-29
EP4244252A1 (en) 2023-09-20
KR20240049348A (ko) 2024-04-16
JP2024532256A (ja) 2024-09-05
JP7591691B2 (ja) 2024-11-28
IL310926A (en) 2024-04-01
FI4244252T3 (fi) 2024-08-29
CN120392998A (zh) 2025-08-01
PL4244252T3 (pl) 2024-11-18
AU2022335719A1 (en) 2024-04-11
AU2022335719B2 (en) 2024-11-28
KR20250036938A (ko) 2025-03-14
CN120420430A (zh) 2025-08-05
TW202327648A (zh) 2023-07-16
ES2991847T3 (es) 2024-12-05
HUE068111T2 (hu) 2024-12-28
IL310926B2 (en) 2025-04-01
WO2023025932A1 (en) 2023-03-02
PT4244252T (pt) 2024-09-03
IL310926B1 (en) 2024-12-01
US20250136676A1 (en) 2025-05-01
CA3229249A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
DK4244252T3 (da) Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof
DK3752780T3 (da) Oxyfuel-klinkerfremstilling uden recirkulation af forvarmerudstødningsgasser
DK3793626T3 (da) Fremgangsmåder til fremstilling af hydrofile kateterenheder med muffe
DK3773558T3 (da) Kombinationsbehandling af artritisk sygdom
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
MA50760A (fr) Intégration de techniques de reconstruction haute fréquence à retard post-traitement réduit
DK4126932T3 (da) Anti-bk-virusantistofmolekyler
DK3774897T3 (da) Fremgangsmåder og systemer til udvælgelse og behandling af patienter med inflammatoriske sygdomme
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
IL282715A (en) Novel antagonistic anti tnfr2 antibody molecules
DK3897646T3 (da) Macitentan til behandling af pulmonal arteriel hypertension
DK3807260T3 (da) Oprensning af nikotin
PL3999119T3 (pl) Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
DK3759745T3 (da) Dannelse af piezoelektriske anordninger
LT3749308T (lt) Klasikine fabri liga sergančių pacientų gydymas migalastatu
DK4179259T3 (da) Kogeplade med sugeorgan
IL311301A (en) Anti-siglec-6 antibodies and methods of use thereof
EP4414388A4 (en) NEW ANTI-L1CAM ANTIBODY
DK4192882T3 (da) Behandling af lupus nephritis med anti-type i inf-receptor-antistof anifrolumab
PL4125843T3 (pl) Leczenie ciężkiego zespołu zapalnego
EP4302809A4 (en) Inhaler
EP3865509A4 (en) RECOMBINANT ANTIBODIES AGAINST HUMAN CARDIAC TROPONIN I
IL312979A (en) Fibrosis treatment with anti-trem2 antibodies
DK3805671T3 (da) Absorption af brændbart kølemiddel
EP4324848A4 (en) HUMAN ANTIBODY TARGETING THE COVID-19 VIRUS